← Back to patent-cliff list
戊酸雌二醇
Tier C — Watch / tradeEstradiol Valerate
远藤制药
Originator
1954
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：ERs
Brand：Climaval、Progynova、补佳乐、Progynon Depot、Estradiol Jenapharm、Estradiol-Depot Jenapharm、Delestrogen
Indications (approved)：雌激素缺乏综合征、前列腺癌、外阴阴道萎缩、性腺功能减退症、血管舒缩症
Regional status
US
批准上市
1954-07-15
EU
批准上市
1996-09-26
China
批准上市
1983-01-01
Japan
批准上市
1954-11-01
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Estradiol Valerate?
Approved indications include: 雌激素缺乏综合征, 前列腺癌, 外阴阴道萎缩, 性腺功能减退症, 血管舒缩症.
When does the Estradiol Valerate patent expire?
No public expiry year is available for Estradiol Valerate yet; this page updates once verified.
How do I get a quote for Estradiol Valerate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25